Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Immutep De nieuwe australische Galapagos ??

582 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 30 »» | Laatste | Omlaag ↓
  1. frederic_knight 23 januari 2021 23:57
    Immutep (NASDAQ:IMMP) drops 6% in premarket after its licensing partners, GlaxoSmithKline (NYSE:GSK), has decided to discontinue its Phase 2 trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, derived from Immutep’s IMP731 antibody, in patients with active ulcerative colitis. The decision is based on the assessment of clinical data as part of a planned interim analysis. GSK is conducting further reporting, assessment and analyses of the efficacy and safety data to determine next steps for the GSK2831781 development program.
    The company’s collaboration with GSK remains in place and GSK2831781 continues to be under an exclusive license with GSK, which has also been explored in another autoimmune disease.
    Under the terms of its ongoing collaboration agreement with GSK, Immutep is eligible to receive up to a total of £54M in remaining developmental milestone payments as well as single-digit tiered royalties, if GSK2831781 is commercialized. GSK is responsible for all costs associated with the clinical development and commercialization of GSK2831781.
    Additionally, the company announced operational and financial position, with $54.9M in cash as at 31 December 2020, providing cash runway beyond the end of calendar year 2022.
    Th Company has also announced its intention to run a new randomized, controlled Phase 2 study in ~160 1st line head and neck squamous cell carcinoma patients which is a more commercially relevant indication. Further details will be announced in due course.

    Bron:
    seekingalpha.com/news/3653491-gsk-pul...
  2. forum rang 4 Dag Trader 25 januari 2021 15:14
    klopt, met GSK hebben ze nog 2 studies lopen, o.a. Psoriasis

    koersreactie vrijdag gelukkig beperkt, komt ook omdat het een bedrijf is met een brede pijplijn denk ik... niet alles kan goed gaan....
    goede financiële basis, hoop mooie dingen in het vooruitzicht... ik hou vast en breid uit waar mogelijk ;-)

  3. forum rang 4 Dag Trader 26 januari 2021 23:50
    MMUTEP ANNOUNCES ADVANCEMENT OF PHASE II TRIAL FOR EFTILAGIMOD ALPHA IN COVID-
    19 PATIENTS TO RANDOMISED PORTION OF THE STUDY
    • Independently reviewed safety run-in data prompts recommendation to initiate enrolment for the
    randomised portion of the Phase II EAT COVID study
    • Up to 110 COVID-19 patients to participate in investigator-initiated study at the University Hospital
    Pilsen, Czech Republic
  4. Mr. T 27 januari 2021 05:33
    Kan iemand meer duiding geven over Immutep op 12 januari 2021. Als ik op Yahoo kijk en ik zet de grafiek op 6 maand dan is er 1 hoge piek te zien. Als ik kijk naar '52 week range' zou hij de 45 AUD hebben aangetikt. Heeft er iemand die dag belachelijk veel geld verdiend of zie ik iets over het hoofd?
  5. forum rang 4 Maisha marefu 27 januari 2021 10:29
    Van de site van immutep.

    Following this data review, the DSMB recommended that the study advance
    with enrolment for the randomised portion of the study. All six patients (age range, 50-83 years; 2 women)
    received the three planned 10 mg efti injections and have since been discharged from hospital. No adverse events have been reported.

    Professor Matejovic, Principal Investigator for the study, stated, “Sadly, hospitals and doctors in the Czech Republic are increasingly overwhelmed and are facing severe challenges treating the high volume of patients
    with COVID-19. Despite this, the DSMB has prioritized the review of the safety data for the first six patients
    in the EAT COVID Phase II study. We are pleased with their recommendation to continue the trial and move
    ahead with the randomised, placebo-controlled portion of the study.”
  6. frederic_knight 27 januari 2021 16:24
    Immutep's lead candidate efti moves forward in mid-stage COVID-19 study
    Jan. 27, 2021 9:20 AM ET

    Immutep's (NASDAQ:IMMP) gains 6% in premarket, after independent Data and Safety Monitoring Board (DSMB) has recommended Phase 2 study evaluating company's lead product candidate eftilagimod alpha (efti) in COVID-19, to advance with enrollment for the randomized portion of the study.
    The recommendation, comes after completion of a safety run-in data of the first six patients in Phase 2 trial, who received the three planned 10 mg efti injections and have since been discharged from hospital. No adverse events have been reported.
    Up to 110 COVID-19 patients will participate in investigator-initiated study at the University Hospital Pilsen, Czech Republic.
582 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 30 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Indices

AEX 789,49 -1,09%
EUR/USD 1,1727 0,00%
Germany30^ 15.514,00 -0,88%
Gold spot 1.754,40 0,00%
LONDEN-FTSE 100 6.963,64 -0,91%
NY-Nasdaq Composite 15.043,97 -0,91%

Stijgers

Accsys
+4,91%
Wereld...
+2,28%
Vastned
+2,13%
Kendrion
+1,81%
Air Fr...
+1,70%

Dalers

Arcelo...
-4,16%
AMG
-3,85%
Avantium
-2,77%
Intert...
-2,54%
CTP
-2,45%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links